跳至主要内容
临床试验/NCT04542577
NCT04542577已完成不适用

Multicenter PMCF Study on the Safety and Performance of PROSPACE 3D / PROSPACE 3D OBLIQUE / TSPACE 3D - A Prospective Study on Total Indications

Aesculap AG2 个研究点 分布在 1 个国家目标入组 208 人开始时间: 2020年9月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Aesculap AG
入组人数
208
试验地点
2
主要终点
Change of Spinal Disability measured by Oswestry Disability Index (ODI)

研究概览

简要总结

Prospective, pure data collection of all PROSPACE 3D, PROSPACE 3D Oblique, TSPACE 3D patients in selected centers (not interventional, multicenter

详细描述

The study collects a data set for each patient receiving a PROSPACE 3D, PROSPACE 3D Oblique, or TSPACE 3D implant. It is intended to collect data preoperatively, intraoperatively and at one follow-up- assessment after a minimum of one year postoperatively containing

  • Basic medical history
  • Type of surgical procedure
  • Treated segments
  • Implant characteristics (including additional implants for anterior/posterior stabilization)
  • Scores: ODI, Pain (VAS), EQ-5D
  • Patient satisfaction

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change of Spinal Disability measured by Oswestry Disability Index (ODI)

时间窗: preoperatively, at 3 months postoperatively and at 12 months postoperatively

The Oswestry Disability Index (ODI) is designed to measure back-specific disability. The questionnaire has 10 items concerning pain and activities of daily living including pain, personal care, lifting, Walking, sitting, standing, sleeping, sex life, social life and travelling. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.

次要结局

  • Side effects(up to 12 months postoperatively)
  • Change of Quality of Life (EQ-5D)(preoperatively, at 3 months postoperatively and at 12 months postoperatively)
  • Change of Pain (VAS)(preoperatively, at 3 months postoperatively and at 12 months postoperatively)
  • Bone fusion(12 Months postoperatively)

研究者

发起方
Aesculap AG
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

PMCF Study on the Safety and Performance of PROSPACE... | 临床试验